CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (Plasma Rich in Growth Factors)

Abstrac number 4CPS-148
Gea. S, Montero. M, Belló. M, Santiuste. A, Rubio. L, Soler. E
Pharmacy Service, Hospital Arnau de Vilanova, Valencia

BACKGROUND

PRGF-Endoret is an autologous preparation obtained from the patient's own blood containing a set of proteins specifically addressed to wound healing and tissue regeneration of the ocular surface. It is used to treat dry eye, often displacing other therapies such as autologous serum.

The **objective** of this study is to evaluate the efficacy and safety of PRGF-Endoret eye drops, as well as patient satisfaction, in patients with dry eyes.

MATERIAL AND METHODS

Retrospective observational study of all patients for whom PRGF-Endoret was requested between February 2019 and October 2019, for the treatment of several disorders with ocular dryness as a symptom.

Demographic and clinical data obtained of the electronic medical history

Age	Treatment start date
Gender	Treatment duration
Indication	Previous treatment
Dosage	Clinical evolution

In addition, two anonymous surveys were conducted based on the Dry Eye Questionnaire (DEQ).

First survey in patients who started treatment, evaluating the frequency of several symptoms: eye dryness, foreign body sensation, eye stinging, pain, eye tingling, blurred vision, eye redness, discomfort to light.

Second survey when renewing the treatment, evaluating the efficacy and safety (taking as measure the appearance of adverse effects) and also the satisfaction with the treatment.

RESULTS

N = 22

SEX

14 (64%) 8 (36%)

Median age of 64 (24-95)

Diagnosis



According to the electronic medical history in **73% of cases the clinical evolution was favorable** in at least three months, requesting treatment renewal in 68%. Only one case reported insomnia as possible adverse effect. Three patients (14%) have not yet completed three months of treatment.

The results of the surveys indicate that **100% of patients were satisfied and noticed improvement in several symptoms**. 50% of patients had previously received autologous serum, 82% of them had a favorable evolution (2 without evaluation).

CONCLUSION

The results indicate that PRGF-Endoret improves dry eye symptoms in our patients and is safe, and patients were satisfied. Patients previously treated with autologous serum had favourable evolution with PRGF-Endoret. Although it is supposed to be more expensive, patients were satisfied with the change.

https://www.eahp.eu/
25-4CPS-148